BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 18548556)

  • 1. Gene expression and methylation status of 14-3-3sigma in human renal carcinoma tissues.
    Liang S; Xu Y; Shen G; Zhao X; Zhou J; Li X; Gong F; Ling B; Fang L; Huang C; Wei Y
    IUBMB Life; 2008 Aug; 60(8):534-40. PubMed ID: 18548556
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Progesterone receptor B gene inactivation and CpG hypermethylation in human uterine endometrial cancer.
    Sasaki M; Dharia A; Oh BR; Tanaka Y; Fujimoto S; Dahiya R
    Cancer Res; 2001 Jan; 61(1):97-102. PubMed ID: 11196205
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Frequent hypermethylation of CpG islands and loss of expression of the 14-3-3 sigma gene in human hepatocellular carcinoma.
    Iwata N; Yamamoto H; Sasaki S; Itoh F; Suzuki H; Kikuchi T; Kaneto H; Iku S; Ozeki I; Karino Y; Satoh T; Toyota J; Satoh M; Endo T; Imai K
    Oncogene; 2000 Nov; 19(46):5298-302. PubMed ID: 11077447
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Quantitative protein expression profiling of 14-3-3 isoforms in human renal carcinoma shows 14-3-3 epsilon is involved in limitedly increasing renal cell proliferation.
    Liang S; Xu Y; Shen G; Liu Q; Zhao X; Xu Z; Xie X; Gong F; Li R; Wei Y
    Electrophoresis; 2009 Dec; 30(23):4152-62. PubMed ID: 19960480
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Wnt signalling in human breast cancer: expression of the putative Wnt inhibitor Dickkopf-3 (DKK3) is frequently suppressed by promoter hypermethylation in mammary tumours.
    Veeck J; Bektas N; Hartmann A; Kristiansen G; Heindrichs U; Knüchel R; Dahl E
    Breast Cancer Res; 2008; 10(5):R82. PubMed ID: 18826564
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Frequent loss of SFRP1 expression in multiple human solid tumours: association with aberrant promoter methylation in renal cell carcinoma.
    Dahl E; Wiesmann F; Woenckhaus M; Stoehr R; Wild PJ; Veeck J; Knüchel R; Klopocki E; Sauter G; Simon R; Wieland WF; Walter B; Denzinger S; Hartmann A; Hammerschmied CG
    Oncogene; 2007 Aug; 26(38):5680-91. PubMed ID: 17353908
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prostate cancer is characterized by epigenetic silencing of 14-3-3sigma expression.
    Lodygin D; Diebold J; Hermeking H
    Oncogene; 2004 Dec; 23(56):9034-41. PubMed ID: 15489902
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Frequent and histological type-specific inactivation of 14-3-3sigma in human lung cancers.
    Osada H; Tatematsu Y; Yatabe Y; Nakagawa T; Konishi H; Harano T; Tezel E; Takada M; Takahashi T
    Oncogene; 2002 Apr; 21(15):2418-24. PubMed ID: 11948426
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Methylation of Tip30 promoter is associated with poor prognosis in human hepatocellular carcinoma.
    Lu B; Ma Y; Wu G; Tong X; Guo H; Liang A; Cong W; Liu C; Wang H; Wu M; Zhao J; Guo Y
    Clin Cancer Res; 2008 Nov; 14(22):7405-12. PubMed ID: 19010857
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Loss of estrogen receptor beta isoform expression and its correlation with aberrant DNA methylation of the 5'-untranslated region in human epithelial ovarian carcinoma.
    Suzuki F; Akahira J; Miura I; Suzuki T; Ito K; Hayashi S; Sasano H; Yaegashi N
    Cancer Sci; 2008 Dec; 99(12):2365-72. PubMed ID: 19032364
    [TBL] [Abstract][Full Text] [Related]  

  • 11. RASSF1A promoter methylation and expression analysis in normal and neoplastic kidney indicates a role in early tumorigenesis.
    Peters I; Rehmet K; Wilke N; Kuczyk MA; Hennenlotter J; Eilers T; Machtens S; Jonas U; Serth J
    Mol Cancer; 2007 Jul; 6():49. PubMed ID: 17634119
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Identification of PRTFDC1 silencing and aberrant promoter methylation of GPR150, ITGA8 and HOXD11 in ovarian cancers.
    Cai LY; Abe M; Izumi S; Imura M; Yasugi T; Ushijima T
    Life Sci; 2007 Mar; 80(16):1458-65. PubMed ID: 17303177
    [TBL] [Abstract][Full Text] [Related]  

  • 13. 14-3-3sigma expression is an independent prognostic parameter for poor survival in colorectal carcinoma patients.
    Perathoner A; Pirkebner D; Brandacher G; Spizzo G; Stadlmann S; Obrist P; Margreiter R; Amberger A
    Clin Cancer Res; 2005 May; 11(9):3274-9. PubMed ID: 15867223
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hypomethylation of the MN/CA9 promoter and upregulated MN/CA9 expression in human renal cell carcinoma.
    Cho M; Uemura H; Kim SC; Kawada Y; Yoshida K; Hirao Y; Konishi N; Saga S; Yoshikawa K
    Br J Cancer; 2001 Aug; 85(4):563-7. PubMed ID: 11506497
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Promoter hypermethylation-mediated inactivation of LRRC4 in gliomas.
    Zhang Z; Li D; Wu M; Xiang B; Wang L; Zhou M; Chen P; Li X; Shen S; Li G
    BMC Mol Biol; 2008 Nov; 9():99. PubMed ID: 18976507
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The role of CpG islands hypomethylation and abnormal expression of neuronal protein synuclein-gamma (SNCG) in ovarian cancer.
    Czekierdowski A; Czekierdowska S; Wielgos M; Smolen A; Kaminski P; Kotarski J
    Neuro Endocrinol Lett; 2006 Jun; 27(3):381-6. PubMed ID: 16816827
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Methylation-associated silencing of SFRP1 in renal cell carcinoma.
    Awakura Y; Nakamura E; Ito N; Kamoto T; Ogawa O
    Oncol Rep; 2008 Nov; 20(5):1257-63. PubMed ID: 18949430
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CMTM5 exhibits tumor suppressor activities and is frequently silenced by methylation in carcinoma cell lines.
    Shao L; Cui Y; Li H; Liu Y; Zhao H; Wang Y; Zhang Y; Ng KM; Han W; Ma D; Tao Q
    Clin Cancer Res; 2007 Oct; 13(19):5756-62. PubMed ID: 17908965
    [TBL] [Abstract][Full Text] [Related]  

  • 19. DNA methylation markers of surfactant proteins in lung cancer.
    Lin Z; Thomas NJ; Bibikova M; Seifart C; Wang Y; Guo X; Wang G; Vollmer E; Goldmann T; Garcia EW; Zhou L; Fan JB; Floros J
    Int J Oncol; 2007 Jul; 31(1):181-91. PubMed ID: 17549420
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CMTM3, located at the critical tumor suppressor locus 16q22.1, is silenced by CpG methylation in carcinomas and inhibits tumor cell growth through inducing apoptosis.
    Wang Y; Li J; Cui Y; Li T; Ng KM; Geng H; Li H; Shu XS; Li H; Liu W; Luo B; Zhang Q; Mok TS; Zheng W; Qiu X; Srivastava G; Yu J; Sung JJ; Chan AT; Ma D; Tao Q; Han W
    Cancer Res; 2009 Jun; 69(12):5194-201. PubMed ID: 19509237
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.